2025 India Autologous Cell Therapy Market Revenue Opportunities Report
Description
The 2025 India Autologous Cell Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market in India include Biocon, Immuneel Therapeutics, Stempeutics Research Pvt. Ltd., and Regen Arthritis Clinic. Biocon is the largest biopharma company in India with a major focus on biologics and biosimilars, including immunotherapy innovations relevant to cell therapies. Immuneel Therapeutics is notable for developing affordable CAR-T cell therapies in India, including technology transferred from Spain for a CD-19 CAR-T approved for lymphoma treatment. Stempeutics Research is a prominent player in Asia Pacific for regenerative medicine and cell therapies. Regen Arthritis Clinic offers diverse autologous stem cell treatments focusing on orthopedic and degenerative conditions.
These companies contribute significantly to the growing autologous cell therapy market in India, which was valued at around USD 22.9 million in 2023 and is projected to reach USD 103.7 million by 2030 with a CAGR of 24.1%. The demand is driven by rising chronic diseases and advances in personalized medicine, where autologous therapies dominate due to immunological advantages and lower rejection rates. Indian companies are leveraging clinical trials, regulatory approvals, and technology partnerships to expand their autologous cell therapy offerings, especially in CAR-T treatments for oncology.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market in India include Biocon, Immuneel Therapeutics, Stempeutics Research Pvt. Ltd., and Regen Arthritis Clinic. Biocon is the largest biopharma company in India with a major focus on biologics and biosimilars, including immunotherapy innovations relevant to cell therapies. Immuneel Therapeutics is notable for developing affordable CAR-T cell therapies in India, including technology transferred from Spain for a CD-19 CAR-T approved for lymphoma treatment. Stempeutics Research is a prominent player in Asia Pacific for regenerative medicine and cell therapies. Regen Arthritis Clinic offers diverse autologous stem cell treatments focusing on orthopedic and degenerative conditions.
These companies contribute significantly to the growing autologous cell therapy market in India, which was valued at around USD 22.9 million in 2023 and is projected to reach USD 103.7 million by 2030 with a CAGR of 24.1%. The demand is driven by rising chronic diseases and advances in personalized medicine, where autologous therapies dominate due to immunological advantages and lower rejection rates. Indian companies are leveraging clinical trials, regulatory approvals, and technology partnerships to expand their autologous cell therapy offerings, especially in CAR-T treatments for oncology.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
